Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers

This study has been terminated.
(Protocol study design was re-done in collaboration with CMS)
Information provided by (Responsible Party):
Cytomedix Identifier:
First received: March 21, 2013
Last updated: October 19, 2016
Last verified: October 2016
The aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, cohort-controlled trial in which venous leg ulcers (VLU)n will be treated using AutoloGel and case-matched against a concurrent cohort of patients receiving undefined Usual and Customary Care (UCC)

Condition Intervention
Venous Leg Ulcer
Device: AutoloGel

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers

Resource links provided by NLM:

Further study details as provided by Cytomedix:

Primary Outcome Measures:
  • Time to wound closure [ Time Frame: 12 weeks ]
    Primary endpoint is time to wound healing after 12 weeks com pared with case matched controls receiving standard of care. Complete wound closure is defined as skin re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart (FDA Guidance for Industry Chronic Cutaneous Ulcer and Burn Wounds ─ Developing Products for Treatment, 2006).

Secondary Outcome Measures:
  • Proportion of wounds healed [ Time Frame: 12 weeks ]
    Comparison of proportion of wounds healed over 12 weeks

  • Frequency of ulcer recurrence [ Time Frame: 1 year ]
    Frequency of ulcer recurrence over a 1 year period post treatment; recurrence is defined as any new ulcer appearing on the leg after the index ulcer has healed.

  • Change in Quality of Life with Chronic Wounds (W-QOL) Score [ Time Frame: 12 weeks ]
    Change in mean Quality of Life with Chronic Wounds (W-QOL) score between baseline and at 12 weeks

  • Number of patients with adverse events as a measure of tolerability [ Time Frame: 12 weeks ]
    Frequency and severity of treatment emergent adverse events

Enrollment: 2
Study Start Date: October 2013
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AutoloGel
Subjects will be treated on average twice a week for the first 2 weeks, and then, once a week thereafter while under active treatment, but actual frequency of treatment will be determined by the treating physician. All subjects will receive Autologel treatment
Device: AutoloGel
Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
Other Name: AutoloGel System

Detailed Description:
Recurrence of ulcers in the leg is common; two-thirds of patients are likely to experience recurring ulcers after the first ulcer. While treatment of the underlying venous disease, depending on the mode of treatment, can lower the recurrence rate in many patients, it does not affect recurrence. AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. The aim of this trial is to demonstrate the effectiveness, measured as complete wound healing, in a prospective, open-label trial in which venous leg ulcers will be treated using AutoloGel and standard of care and case-matched against a concurrent cohort of patients receiving undefined Usual and Customary Care

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Medicare/Medicaid eligible
  2. ≥18 years of age
  3. Proven venous disease
  4. The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (Index Ulcer) that is located between and including the knee and the ankle
  5. For subjects with potentially multiple eligible VLUs, the largest ulcer will be selected. There must be at least 4 cm between the Index Ulcer and other ulcers; if all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure)
  6. Debrided ulcer size between 2 cm2 and 200 cm2
  7. Demonstrated adequate compression regimen
  8. Duration ≥ 1 month at first visit
  9. Subject must be willing to comply with the Protocol, which will be assessed by enrolling clinician.

Exclusion Criteria:

  1. Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin
  2. Presence of another wound that is concurrently treated and might interfere with treatment of index wound by AutoloGel
  3. Ulcer not of VLU pathophysiology (e.g., pure diabetic, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology)
  4. Any malignancy other than non-melanoma skin cancer
  5. Subjects who are cognitively impaired and do not have a healthcare proxy
  6. Serum albumin of less than 2.5 g/dL
  7. Plasma Platelet count of less than 100 x 109/L
  8. Hemoglobin of less than 10.5 g/dL
  9. Subject has inadequate venous access for repeated blood draw required for AutoloGel Administration
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01817543

United States, California
Arcadia, California, United States, 91007
United States, Georgia
HyperBarxs at Northside Forsyth
Cumming, Georgia, United States
Sponsors and Collaborators
  More Information

Responsible Party: Cytomedix Identifier: NCT01817543     History of Changes
Other Study ID Numbers: CM003
Study First Received: March 21, 2013
Last Updated: October 19, 2016

Keywords provided by Cytomedix:
venous leg ulcers
non healing wounds

Additional relevant MeSH terms:
Leg Ulcer
Varicose Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Varicose Veins
Vascular Diseases
Cardiovascular Diseases processed this record on May 22, 2017